Early Versus Late Administration of Long-Acting Insulin in Adult Diabetic Ketoacidosis
Annals of Pharmacotherapy · 2025
DOI: 10.1177/10600280241278371 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Annals of Pharmacotherapy, 2025. Verfasst von Michael M Do und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Services, Corewell Health William Beaumont University Hospital, Royal Oak, MI, USA. Hauptthemen laut MEDLINE: Diabetic Ketoacidosis, Hypoglycemic Agents, Insulin, Long-Acting. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben.
Abstract (Originalsprache)
Background
Evidence is inconclusive if early administration of subcutaneous (SQ) long-acting insulin (LAI) in management of diabetic ketoacidosis (DKA) improves outcomes.
Objective
This study compares early versus late administration of SQ LAI in time to DKA resolution.
Methods
This single-center, retrospective study included patients with DKA who received ≥12 hours of continuous intravenous insulin (CIVI) with LAI overlap. Patients were compared based on LAI administration time to CIVI initiation: Early ( 7.35, or serum carbon dioxide >15 mEq/L. Outcomes included time to DKA resolution, length of stay (LOS), CIVI duration, and adverse events.
Results
A total of 27 patients were included in each group. Baseline characteristics were similar between both groups. There was no difference in time to DKA resolution, Early = 17.6 (13.9-26.8) hours versus Late = 19.2 (17.1-32.1) hours, P = 0.16. The Early group had shorter CIVI duration (Early = 19.5 ± 10.3 hours vs Late = 25.6 ± 8.4 hours, P = 0.02) and received less intravenous (IV) fluids in the first 36 hours (Early = 4.04 ± 2.12 L vs Late = 5.85 ± 2.24 L, P = 0.004). No differences were identified with adverse events, including hypoglycemia, or LOS. Conclusion and Relevance: Administration of SQ LAI < 12 hours did not decrease time to DKA resolution or LOS. Patients in the Early group had received a lower dose of LAI, shorter duration of CIVI infusion, and required less IV fluids within 36 hours of admission. This study supports the need for further research to determine the potential benefits of administering SQ insulin early in managing DKA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Services, Corewell Health William Beaumont University Hospital, Royal Oak, MI, USA.
- Wayne State University Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, USA.
ORCID-Profile: Michael M Do
Zitieren
APA
Do, M. M., Fleury, J. A., Morgan, G. P., Hall Zimmerman, L., Hanni, C. M., Sulaiman, H., & Lutz, M. F. (2025). Early Versus Late Administration of Long-Acting Insulin in Adult Diabetic Ketoacidosis. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280241278371
Vancouver
Do MM, Fleury JA, Morgan GP, Hall Zimmerman L, Hanni CM, Sulaiman H, et al. Early Versus Late Administration of Long-Acting Insulin in Adult Diabetic Ketoacidosis. Annals of Pharmacotherapy. 2025. doi:10.1177/10600280241278371
BibTeX
@article{Do2025,
author = {Do, Michael M and Fleury, Jacklyn A and Morgan, Grant P and Hall Zimmerman, Lisa and Hanni, Claudia M and Sulaiman, Hiba and Lutz, Mark F},
title = {Early Versus Late Administration of Long-Acting Insulin in Adult Diabetic Ketoacidosis},
journal = {Annals of Pharmacotherapy},
year = {2025},
doi = {10.1177/10600280241278371}
}
EUVIMED